… a novel Lyme borreliosis vaccine candidate (VLA15) targeting the six most common outer
surface protein A (OspA) … a multivalent Lyme borreliosis vaccine candidate that was safe and …

… afzelii OspA ST2, the most important Borrelia species … that the novel multivalent OspA-based
vaccine approach has the … of the linker sequence to immunogenicity and protection was …

… Conclusions: The OspA vaccine against Lyme disease is safe and its immunogenicity and
… on a newgeneration, multivalent OspA-based Lyme borreliosis vaccine intended to protect …

… The V H Hs displayed unique reactivity profiles with the seven OspA … OspA serotypes that
should be considered when designing and evaluating multivalent Lyme disease vaccines. …

… In order to improve the OspA ST3 specific immunogenicity as well as the yield of the fusion
… Subsequently, immune sera obtained from the clinical trial with the multivalent OspA vaccine …

… Nanoparticle delivery of the OspA antigen is a novel vaccine approach to Lyme disease. We
… , OspA, in its natural conformation in an ordered multivalent array to improve immunogenicity…

… the current modifications of recombinant OspA to develop a multivalent subunit vaccine for
Lyme … The safety and immunogenicity of the rOspA vaccine was again tested in 30 healthy …

… the monovalent and multivalent LB vaccines result in mild … multivalent vaccine slightly more
tolerable than the monovalent one. Both vaccine classes were similarly highly immunogenic. …

… serum antibody titers against a single epitope near the C-terminus of OspA, as … OspA following
vaccination remains undefined even as next-generation multivalent OspA-based vaccines …

… Lyme disease vaccine based on lipidated recombinant OspA, … Multivalent approaches in
Lyme disease vaccines have … Immunogenicity of Lyme disease vaccinogens can potentially be …